Tamoxifen does not prevent the mobilization of body lipids elicited by oleoyl-estrone.
Oleoyl-estrone is a powerful, slimming adipose tissue-derived signal that has biological effects widely opposed to those of its estrone moiety. The present experiment was designed to determine whether oleoyl-estrone effects on body energy are mediated by the estrogen receptor, blocked with the antagonist tamoxifen. Male Wistar rats were given daily oral doses of 10 micromol/kg d of oleoyl-estrone in oil containing 0 or 0.40 mg/kg d of tamoxifen. The data were compared with controls receiving only oil or 50 nmol/kg d of free estrone. After 10 days, the rats were killed, and their body composition and plasma metabolites and hormones were analyzed. Rats receiving estrone increased their body energy and lipid content compared with controls. Both groups of oleoyl-estrone-treated rats lost body weight, energy, and lipid; the losses in the rats receiving tamoxifen alone were less marked than in those receiving oleoyl-estrone. No significant changes in plasma glucose or triacylglycerols were observed. The patterns of change of estrone sulphate, estradiol, and oleoyl-estrone were consistent with a noticeable hydrolysis of oleoyl-estrone. The lack of differences in the fat mass in oleoyl-estrone-treated rats irrespective of the presence of tamoxifen suggested that the estrogenic pathway was not responsible for the slimming effects observed. Thus, it can be concluded that oleoyl-estrone effects are not mediated through its conversion to estrone or estradiol acting through the estrogen receptor. Tamoxifen partly mimicked the slimming effects of oleoyl-estrone; this could be speculatively explained by tamoxifen acting through the oleoyl-estrone signalling pathway.
Ferrer-Lorente
Raquel
R
Department of Nutrition and Food Science, Faculty of Biology, University of Barcelona. Av. Diagonal 645, 08028 Barcelona, Spain.
García-Peláez
Beatriz
B
Fernández-López
José Antonio
JA
Remesar
Xavier
X
Alemany
Marià
M
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000494:pharmacology; D004970:Estrone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology*; D008053:Lipid Mobilization / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009829:Oleic Acids / Q000097:blood / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000502:physiology; D013629:Tamoxifen / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D019440:Anti-Obesity Agents; D001786:Blood Glucose; D004965:Estrogen Antagonists; D009829:Oleic Acids; D011960:Receptors, Estrogen; D014280:Triglycerides; D013629:Tamoxifen; D004970:Estrone; D004958:Estradiol; C108709:oleoyl-estrone; C017296:estrone sulfate